Lupin receives tentative approval for Generic Livalo Tablets

30 Dec 2016 Evaluate

Pharma Major Lupin has received tentative approval for its Pitavastatin Tablets, 1 mg, 2 mg, and 4 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Kowa Company’s Livalo Tablets 1 mg, 2 mg and 4 mg. The filing is from company’s Pithampur (Indore) manufacturing facility. 

The company’s Pitavastatin Tablets, 1 mg, 2 mg and 4 mg are the AB rated generic equivalent of Kowa's Livalo Tablets, 1 mg, 2 mg and 4 mg. Pitavastatin Tablets are indicated as an adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Livalo Tablets had US sales of $245.3 million as per IMS MAT Sep 2016.

Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.

Lupin Share Price

2073.10 -32.75 (-1.56%)
05-Jan-2026 15:52 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1730.15
Dr. Reddys Lab 1248.55
Cipla 1519.30
Zydus Lifesciences 922.00
Lupin 2073.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×